Charonpongsuntorn C.; Tanasanvimon S.; Korphaisarn K.; Payapwattanawong S.; Siripoon T.; Pakvisal N.; Juengsamarn J.; Phaibulvatanapong E.; Chindaprasirt J.; Prasongsook N.; Udomdamrongkul K.; Ngamphaiboon N.; Sirachainan E.
(NLM (Medline), 2022)
PURPOSE: Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet ...